News
We send the latest information from SMC Laboratories.
SMC will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023)
We are pleased to announce that SMC Laboratories will be exhibiting at The 31st Japan Digestive Disease Week (…
Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Mon…
Study published in Biomed Pharmacother. on the effects of GRP119 agonist in the treatment of NASH in STAM™ mice
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre…
Exciting News from 89bio, Inc.! U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in NASH
The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new dru…
SMC at BioJapan 2023 in October!
We are pleased to announce that SMC Laboratories will be attending the BioJapan 2023 from October 11th (W…
SMC attend The Digital Partnering in BioPharm America!
We are pleased to announce that SMC Laboratories will be attending the BioPharm America Partnering Event …
Acute Liver Failure Mouse Model Lineup
Acute liver failure (ALF) carries a high mortality of approximately 40%, which is caused by virus infections (…
Study published in Front Immunol. on co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis in STAM™
We are pleased to introduce a study on non-alcoholic steatohepatitis (NASH) may promote the development and ex…
Announcement of webinar 【New NAFLD nomenclature ~Redefining the NAFLD/NASH mouse model~】
Today, we are excited to invite you to join our Webinar that will be taking place on August 18th from 9:30 AM …
Redefinition from NAFLD/NASH to MASLD/MASH
The American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the…